| Date Filed | Type | Description |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/30/2023 |
4
| MISSLING CHRISTOPHER U (President and CEO) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.|
Txns:
| Sold 268,000 shares
@ $7.9825, valued at
$2.1M
Exercised 268,000 options to buy
@ $1.6, valued at
$428.8k
Exercised 232,000 options to buy
@ $1.6, valued at
$371.2k
|
|
| 05/24/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/14/2023 |
8-K
| Quarterly results |
| 04/04/2023 |
4
| Ma Jiong (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.|
Txns:
| Granted 50,000 options to buy
@ $8.57, valued at
$428.5k
|
|
| 04/04/2023 |
4
| Thomas Steffen (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.|
Txns:
| Granted 50,000 options to buy
@ $8.57, valued at
$428.5k
|
|
| 04/04/2023 |
4
| Velden Claus Vander (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.|
Txns:
| Granted 50,000 options to buy
@ $8.57, valued at
$428.5k
|
|
| 04/04/2023 |
4
| Donhauser Peter D.O. (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.|
Txns:
| Granted 50,000 options to buy
@ $8.57, valued at
$428.5k
|
|
| 04/04/2023 |
4
| Skarpelos Athanasios (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.|
Txns:
| Granted 50,000 options to buy
@ $8.57, valued at
$428.5k
|
|
| 04/04/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/04/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 5.3% stake in Anavex Life Sciences Corp. |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/07/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/07/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 01/31/2023 |
SC 13G/A
| BlackRock Inc. reports a 7.2% stake in ANAVEX LIFE SCIENCES CORP |
| 01/27/2023 |
10-K/A
| Annual Report for the period ended September 30, 2022 [amend] |
| 12/02/2022 |
8-K
| Quarterly results |
| 11/28/2022 |
10-K
| Annual Report for the period ended September 30, 2022 |
| 08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/29/2022 |
4
| Velden Claus Vander (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.|
Txns:
| Granted 50,000 options to buy
@ $10.09, valued at
$504.5k
|
|
| 06/29/2022 |
4
| Thomas Steffen (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.|
Txns:
| Granted 50,000 options to buy
@ $10.09, valued at
$504.5k
|
|
| 06/29/2022 |
4
| Donhauser Peter D.O. (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.|
Txns:
| Granted 50,000 options to buy
@ $10.09, valued at
$504.5k
|
|
| 06/29/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/29/2022 |
4
| Ma Jiong (Director) has filed a Form 4 on ANAVEX LIFE SCIENCES CORP.|
Txns:
| Granted 50,000 options to buy
@ $10.09, valued at
$504.5k
|
|
| 06/10/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/27/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/11/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/11/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/08/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|